NEW YORK (GenomeWeb) – MDxHealth reported Thursday that its total full-year 2017 revenues rose 35 percent, led by sales of its ConfirmMDx for prostate cancer test, which accounted for 91 percent of sales volumes.

For the 12 months ended Dec. 31, the company reported total revenues of $40.5 million, up from $30.0 million in 2016. Revenue included the sale of the company's colorectal cancer patents to Exact Sciences. Excluding revenue from that sale for both periods, total products and services revenue rose approximately 13 percent to $28.2 million during 2017.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.